SynCore Biotechnology Co (ROCO:4192) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4192 SynCore Biotechnology Co Ltd ROCO:4192
69 GF Score
Price NT$18.60
GF Value NT$40.83
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is SynCore Biotechnology Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


SynCore Biotechnology Co  (ROCO:4192) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


SynCore Biotechnology Co Cyclically Adjusted PS Ratio Related Terms


SynCore Biotechnology Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for SynCore Biotechnology Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynCore Biotechnology Co Cyclically Adjusted PS Ratio Chart

SynCore Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 244.24 183.51 65.98 56.39 43.01

SynCore Biotechnology Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.13 48.53 42.64 34.14 32.98

ROCO:4192 vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, SynCore Biotechnology Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynCore Biotechnology Co Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynCore Biotechnology Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where SynCore Biotechnology Co's Cyclically Adjusted PS Ratio falls into.


ROCO:4192
69GF Score
SynCore Biotechnology Co Ltd ROCO:4192
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynCore Biotechnology Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

SynCore Biotechnology Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, SynCore Biotechnology Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.178/333.9520*333.9520
=0.178

Current CPI (Jun. 2026) = 333.9520.

SynCore Biotechnology Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.100 241.428 0.138
201612 0.106 241.432 0.147
201703 0.097 243.801 0.133
201706 0.120 244.955 0.164
201709 0.108 246.819 0.146
201712 0.105 246.524 0.142
201803 0.096 249.554 0.128
201806 0.103 251.989 0.137
201809 0.094 252.439 0.124
201812 0.085 251.233 0.113
201903 0.286 254.202 0.376
201906 0.103 256.143 0.134
201909 0.082 256.759 0.107
201912 0.080 256.974 0.104
202003 0.079 258.115 0.102
202006 0.060 257.797 0.078
202009 0.136 260.280 0.174
202012 0.196 260.474 0.251
202103 0.044 264.877 0.055
202106 0.041 271.696 0.050
202109 0.047 274.310 0.057
202112 0.092 278.802 0.110
202203 0.108 287.504 0.125
202206 0.093 296.311 0.105
202209 0.144 296.808 0.162
202212 0.163 296.797 0.183
202303 0.119 301.836 0.132
202306 0.145 305.109 0.159
202309 0.185 307.789 0.201
202312 0.176 306.746 0.192
202403 0.124 312.332 0.133
202406 0.201 314.175 0.214
202409 0.150 315.301 0.159
202412 0.187 315.605 0.198
202503 0.153 319.799 0.160
202506 0.222 322.561 0.230
202509 0.184 324.800 0.189
202512 0.210 324.054 0.216
202603 0.174 330.213 0.176
202606 0.178 333.952 0.178

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is SynCore Biotechnology Co (ROCO:4192) Overvalued in 2026?

Based on GuruFocus' analysis, SynCore Biotechnology Co stock appears to be undervalued. The current stock price of NT$18.60 is trading 54.4% below its estimated GF Value™ of NT$40.83. GuruFocus considers SynCore Biotechnology Co to be Significantly Undervalued.

Key valuation signals for ROCO:4192:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: NT$40.83 vs. price of NT$18.60 (54.4% below fair value)
  • GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SynCore Biotechnology Co Business Description

Address No. 84 Zhongshan Road, Zhongshan Village, Dongshan Township, Yilan, TWN, 269
SynCore Biotechnology Co Ltd is a biotechnology company. The pipeline products of the company include SB01 and 02, SB03, SB04, SB05, and Others. It is engaged in new drug development and sales, healthy food development and sales, medicine inspection, biotechnology services, and intellectual property. It operates in a single industry, the new drug development. The company generates the majority of its revenue from medical products and healthy food.
69GF Score

Get the complete analysis for ROCO:4192

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.60
Price
NT$40.83
GF Value